France Liquid Biopsy Market Size & Outlook, 2024-2030
Related Markets
France liquid biopsy market highlights
- The France liquid biopsy market generated a revenue of USD 311.6 million in 2024 and is expected to reach USD 610.8 million by 2030.
- The France market is expected to grow at a CAGR of 11.8% from 2025 to 2030.
- In terms of segment, blood sample based was the largest revenue generating type in 2024.
- Blood Sample Based is the most lucrative type segment registering the fastest growth during the forecast period.
Liquid biopsy market data book summary
| Market revenue in 2024 | USD 311.6 million |
| Market revenue in 2030 | USD 610.8 million |
| Growth rate | 11.8% (CAGR from 2025 to 2030) |
| Largest segment | Blood sample based |
| Fastest growing segment | Blood Sample Based |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Blood Sample Based |
| Key market players worldwide | ANGLE PLC, Guardant Health Inc, Myriad Genetics Inc, Biocept Inc, Lucence Health, Roche, Qiagen NV, Illumina Inc, Thermo Fisher Scientific Inc, Epigenomics AG, Oncimmune, Freenome |
Other key industry trends
- In terms of revenue, France accounted for 2.6% of the global liquid biopsy market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Europe, Germany liquid biopsy market is projected to lead the regional market in terms of revenue in 2030.
- UK is the fastest growing regional market in Europe and is projected to reach USD 1,624.3 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy Market Scope
Liquid Biopsy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Freenome | View profile | 501-1000 | South San Francisco, California, United States, North America | https://www.freenome.com |
| Oncimmune | View profile | 51-100 | Nottingham, Nottingham, United Kingdom, Europe | http://oncimmune.com/ |
| Lucence Health | View profile | 51-100 | Palo Alto, California, United States, North America | https://www.lucence.com/ |
| Roche | View profile | 10001+ | Basel, Basel-Stadt, Switzerland, Europe | http://www.roche.com |
| Epigenomics AG | View profile | 18 | Geneststrasse 5, Berlin, BB, Germany, 10829 | https://www.epigenomics.com |
| Guardant Health Inc | View profile | 1779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | https://www.guardanthealth.com |
| Biocept Inc | View profile | 50 | 9955 Mesa Rim Road, San Diego, CA, United States, 92121 | https://www.biocept.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
| ANGLE PLC | View profile | 165 | 10 Nugent Road, The Surrey Research Park, Surrey, Guildford, United Kingdom, GU2 7AF | https://www.angleplc.com |
| Qiagen NV | View profile | 5900 | Hulsterweg 82, Venlo, LI, Netherlands, 5912 PL | https://www.qiagen.com |
| Illumina Inc | View profile | 9300 | 5200 Illumina Way, San Diego, CA, United States, 92122 | https://www.illumina.com |
| Thermo Fisher Scientific Inc | View profile | 122000 | 168 Third Avenue, Waltham, MA, United States, 02451 | https://www.thermofisher.com |
France liquid biopsy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy market will help companies and investors design strategic landscapes.
Blood sample based was the largest segment with a revenue share of 81.61% in 2024. Horizon Databook has segmented the France liquid biopsy market based on blood sample based covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of France market can primarily be attributed to extensive government initiatives that are boosting the adoption of liquid biopsy solutions in the country. Since 2013, the French National Cancer Institute (INCa) has supported the implementation of targeted NGS as part of routine clinical practice.
Moreover, in September 2023, Roche France, in partnership with the Institute Gustave Roussy and Foundation Medicine, Inc., announced the establishment of in-house liquid biopsy testing in France with the utilization of Foundation Medicine’s FoundationOne Liquid CDx to provide genomic testing to cancer patients in the country.
The growing cancer prevalence and increasing burden of chronic diseases on the healthcare industry are further anticipated to drive market growth. In October 2022, the My Personal Breast Cancer Screening (MyPeBS) clinical trial was conducted in Belgium, which aimed to evaluate a breast cancer screening plan based on individual risk.
Reasons to subscribe to France liquid biopsy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of France liquid biopsy market databook
-
Our clientele includes a mix of liquid biopsy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the France liquid biopsy market , including forecasts for subscribers. This country databook contains high-level insights into France liquid biopsy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
France liquid biopsy market size, by type, 2018-2030 (US$M)
France Liquid Biopsy Market Outlook Share, 2024 & 2030 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
